Helicobacter pylori Infection Market to Register Incremental Growth During the Forecast Period (2023-2032), Asserts DelveInsight | Takeda, RedHill Biopharma, Elpen Pharma, TenNor Therapeutics, Phathom

DelveInsight’s “Helicobacter pylori Infection Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Helicobacter pylori Infection, historical and forecasted epidemiology as well as the Helicobacter pylori Infection market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Helicobacter pylori Infection market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Helicobacter pylori Infection Market Forecast

Some of the key facts of the Helicobacter pylori Infection Market Report: 

• The Helicobacter pylori Infection market size was valued approximately USD 3,489 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In the US, the H. pylori infections market size was valued at over USD 1,579 million in 2022, and it is projected to grow even more by 2032
• Approximately 322,760,143 cases of H. pylori infection were identified as predominant cases in the 7MM in 2022; over the study period (2019–2022), it is anticipated that this number will rise to 2032
• Approximately 37% of all diagnosed prevalent instances of H. pylori infection in the 7MM occurred in the US in 2022, and this percentage is predicted to rise by 2032
• With around 32,035,114 cases, France had the greatest diagnosed prevalence of H. pylori infection among the EU4 and the UK in 2022, while the UK had the lowest diagnosed prevalence of H. pylori infection with approximately 24,045,610 cases
• As of 2022, the estimated prevalence of H. pylori infection in Japan was 64,169,348. During the 2019–2032 study period, this number is anticipated to decline
• Estimates for the gender distribution of the disease indicate a male majority across the 7MM, with roughly 62,858,703 male and 57,235,033 female cases in the US in 2022, based on DelveInsight’s epidemiology model for H. pylori infection
• There are only a few late-stage products in the developing pipeline for H. pylori infection that could be released within the projected period (2023–2032). Numerous treatments, including Finafloxacin, Ceclezepide, Tegoprazan/RQ-00000004, SQ109, SVT-1C4610, and BGA-1901, are being developed at different stages
• Key Helicobacter pylori Infection Companies: Elpen Pharmaceutical, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others
• Key Helicobacter pylori Infection Therapies: Esomeprazole, TNP-2198, Vonoprazan, Tegoprazan, Levofloxacin, Lansoprazole (Lanton), Vonoprazan, RHB-105, rabeprazole sodium, TAK-438, Ilaprazole + Amoxicillin, Omeprazole, amoxicillin, clarithromycin, and others
• The Helicobacter pylori Infection epidemiology based on gender analyzed that there is a higher male preponderance in the prevalence of H. pylori infection
• The Helicobacter pylori Infection market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Helicobacter pylori Infection pipeline products will significantly revolutionize the Helicobacter pylori Infection market dynamics.

Helicobacter pylori Infection Overview

Helicobacter pylori, also known as H. pylori, is a spiral-shaped, flagellated, gram-negative bacteria that mostly affects the small intestine and stomach of humans. Typically acquired during childhood, this is one of the most prevalent chronic bacterial infections globally, with the majority of infected persons remaining asymptomatic.

Get a Free sample for the Helicobacter pylori Infection Market Report 

https://www.delveinsight.com/report-store/helicobacter-pylori-h-pylori-infection-market

Helicobacter pylori Infection Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Helicobacter pylori Infection Epidemiology Segmentation:

The Helicobacter pylori Infection market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Helicobacter pylori Infection
• Prevalent Cases of Helicobacter pylori Infection by severity
• Gender-specific Prevalence of Helicobacter pylori Infection
• Diagnosed Cases of Episodic and Chronic Helicobacter pylori Infection

Download the report to understand which factors are driving Helicobacter pylori Infection epidemiology trends @ Helicobacter pylori Infection Epidemiology Forecast

Helicobacter pylori Infection Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Helicobacter pylori Infection market or expected to get launched during the study period. The analysis covers Helicobacter pylori Infection market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Helicobacter pylori Infection Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Helicobacter pylori Infection Therapies and Key Companies

• Esomeprazole: Elpen Pharmaceutical
• TNP-2198: TenNor Therapeutics
• Vonoprazan: Phathom Pharmaceuticals
• Tegoprazan: HK inno.N Corporation
• Levofloxacin: Deva Holding A.S.
• Lansoprazole (Lanton): Meridian Bioscience, Inc.
• Vonoprazan: Takeda
• RHB-105: RedHill Biopharma
• rabeprazole sodium: Janssen Cilag Pharmaceutica
• TAK-438: Takeda
• Ilaprazole + Amoxicillin: Il-Yang Pharm
• Omeprazole, amoxicillin, clarithromycin: Forest Laboratories

Discover more about therapies set to grab major Helicobacter pylori Infection market share @ Helicobacter pylori Infection Treatment Market

Helicobacter pylori Infection Market Strengths

• Several regimens such as bismuth, sequential therapy, concomitant therapy, and others have become available which will help improve the treatment and overcome the limitations of first-line Clarithromycin-based triple therapy
• The developments of current diagnostic methods allow to have a more accurate diagnosis of H. pylori infection, which helps in improving the management of H. pylori-associated diseases

Helicobacter pylori Infection Market Opportunities

• Considering the high prevalence of H. pylori infection, there is tremendous opportunity for pharma companies to develop prophylactic or therapeutic vaccines for H. pylori.
• There is an opportunity to come up with more feasible and reliable diagnostic modalities of H. pylori infection in the future.

Scope of the Helicobacter pylori Infection Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Helicobacter pylori Infection Companies: Elpen Pharmaceutical, TenNor Therapeutics, Phathom Pharmaceuticals, HK inno.N Corporation, Deva Holding A.S., Meridian Bioscience, Inc., Takeda, RedHill Biopharma, Janssen Cilag Pharmaceutica, Takeda, Il-Yang Pharm, Forest Laboratories, and others
• Key Helicobacter pylori Infection Therapies: Esomeprazole, TNP-2198, Vonoprazan, Tegoprazan, Levofloxacin, Lansoprazole (Lanton), Vonoprazan, RHB-105, rabeprazole sodium, TAK-438, Ilaprazole + Amoxicillin, Omeprazole, amoxicillin, clarithromycin, and others
• Helicobacter pylori Infection Therapeutic Assessment: Helicobacter pylori Infection current marketed and Helicobacter pylori Infection emerging therapies
• Helicobacter pylori Infection Market Dynamics: Helicobacter pylori Infection market drivers and Helicobacter pylori Infection market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Helicobacter pylori Infection Unmet Needs, KOL’s views, Analyst’s views, Helicobacter pylori Infection Market Access and Reimbursement 

To know more about Helicobacter pylori Infection companies working in the treatment market, visit @ Helicobacter pylori Infection Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Helicobacter pylori Infection Market Report Introduction

2. Executive Summary for Helicobacter pylori Infection

3. SWOT analysis of Helicobacter pylori Infection

4. Helicobacter pylori Infection Patient Share (%) Overview at a Glance

5. Helicobacter pylori Infection Market Overview at a Glance

6. Helicobacter pylori Infection Disease Background and Overview

7. Helicobacter pylori Infection Epidemiology and Patient Population

8. Country-Specific Patient Population of Helicobacter pylori Infection 

9. Helicobacter pylori Infection Current Treatment and Medical Practices

10. Helicobacter pylori Infection Unmet Needs

11. Helicobacter pylori Infection Emerging Therapies

12. Helicobacter pylori Infection Market Outlook

13. Country-Wise Helicobacter pylori Infection Market Analysis (2019–2032)

14. Helicobacter pylori Infection Market Access and Reimbursement of Therapies

15. Helicobacter pylori Infection Market Drivers

16. Helicobacter pylori Infection Market Barriers

17.  Helicobacter pylori Infection Appendix

18. Helicobacter pylori Infection Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services